Physician profile
Gary W Edelson
NPI 1952392599
$503,093.92
in general payments reported to CMS, 2019-2025
59 companies · $129K in 2025
The $129K reported for 2025 was more than what 99% of Endocrinology, Diabetes & Metabolism providers received nationally (typical 2025 total: $506).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $166K · 2020: $55K · 2021: $33K · 2022: $23K · 2023: $62K · 2024: $35K · 2025: $129K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $166K · Travel and Lodging: $25K · Food and Beverage: $17K · Honoraria: $11K · Consulting Fee: $8,363 · Education: $15.50.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $165,900.95 |
| Travel and Lodging | $25,219.91 |
| Food and Beverage | $16,653.92 |
| Honoraria | $10,548.00 |
| Consulting Fee | $8,362.50 |
| Education | $15.50 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $175,916.19 | 2019-2025 | Evenity, Uplizna, Tepezza |
| Ascendis Pharma Endocrinology INC | $123,374.14 | 2022-2025 | Yorvipath |
| Lilly USA, LLC | $85,818.31 | 2019-2025 | Jardiance, Mounjaro, Zepbound |
| Astrazeneca Pharmaceuticals LP | $24,167.14 | 2019-2023 | Farxiga |
| Boehringer Ingelheim Pharmaceuticals, INC. | $22,901.01 | 2019-2025 | Jardiance |
| Radius Health, INC. | $22,680.00 | 2019-2025 | Tymlos |
| Corcept Therapeutics | $15,466.46 | 2019-2025 | Korlym |
| Kyowa Kirin, INC. | $9,406.74 | 2025 | |
| Horizon Therapeutics Plc | $4,102.42 | 2019-2023 | Tepezza |
| Janssen Pharmaceuticals, INC | $3,195.70 | 2019-2020 | |
| Cequr Corporation | $3,074.82 | 2023-2025 | Cequr Simplicity |
| Abbott Laboratories | $2,254.14 | 2020-2025 | Freestyle Libre Pro, Freestyle Libre 3, Proclaim |
| Novo Nordisk INC | $2,090.28 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Alexion Pharmaceuticals, INC. | $1,317.25 | 2021-2025 | Strensiq |
| Abbvie INC. | $1,293.85 | 2019-2025 | Synthroid |
Show all 59 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Sanofi-Aventis U.S. LLC | $889.07 | 2019-2025 | |
| Antares Pharma, INC. | $519.99 | 2019-2025 | Xyosted, Tlando, Nocdurna |
| Mannkind Corporation | $438.90 | 2019-2025 | Afrezza |
| Dexcom, INC. | $416.96 | 2019-2025 | Dexcom G6 Transmitter |
| Amryt Pharma Holdings LTD | $294.02 | 2022-2023 | Mycapssa |
| Amneal Pharmaceuticals LLC | $285.04 | 2019-2025 | Unithroid |
| Alvogen INC | $265.98 | 2022-2025 | Teriparatide |
| Merck Sharp & Dohme LLC | $230.89 | 2019-2023 | Verquvo, Steglujan, Januvia |
| Bayer Healthcare Pharmaceuticals INC. | $213.27 | 2021-2023 | |
| Pfizer INC. | $198.99 | 2019-2025 | |
| Madrigal Pharmaceuticals | $165.00 | 2024-2025 | Rezdiffra, Resmetirom |
| Neurocrine Biosciences, INC. | $157.83 | 2024-2025 | |
| Amphastar Pharmaceuticals, INC. | $153.42 | 2023-2025 | Baqsimi |
| Recordati_rare_diseases_inc. | $135.36 | 2021-2025 | Isturisa, Signifor Lar |
| Xeris Pharmaceuticals, INC. | $134.35 | 2020-2025 | Recorlev |
| Ipsen Biopharmaceuticals, INC | $127.01 | 2019-2022 | |
| Medtronic, INC. | $121.21 | 2022-2025 | Minimed 780g |
| Clarus Therapeutics INC. | $117.30 | 2021 | |
| Insulet Corporation | $112.15 | 2019-2025 | Omnipod |
| Shire North American Group INC | $111.82 | 2019 | |
| Nevro Corp. | $110.37 | 2021-2023 | Senza |
| Lifescan, INC. | $96.09 | 2020-2023 | |
| Halozyme INC | $91.94 | 2023 | |
| Takeda Pharmaceuticals U.S.A., INC. | $89.94 | 2020 | |
| Ibsa Pharma INC. | $80.43 | 2019-2022 | |
| Chiesi USA, INC. | $57.31 | 2024-2025 | Mycapssa |
| Verity Pharmaceuticals INC. | $53.58 | 2025 | Tlando |
| Tolmar, INC. | $43.22 | 2023-2024 | |
| Zealand Pharma US, INC. | $41.58 | 2021-2022 | |
| Novartis Pharmaceuticals Corporation | $31.74 | 2023-2024 | |
| Ultragenyx Pharmaceutical INC. | $28.78 | 2019-2021 | |
| Averitas Pharma INC. | $21.32 | 2023 | Qutenza |
| Companion Medical, INC. | $20.88 | 2020 | |
| Sequel Med Tech, LLC | $19.91 | 2025 | Twiist |
| Allergan, INC. | $19.50 | 2019 | |
| Esperion Therapeutics, INC. | $19.36 | 2020 | |
| Glaxosmithkline, LLC. | $18.18 | 2025 | Shingrix |
| Ascend Therapeutics US, LLC | $18.00 | 2021 | |
| Tandem Diabetes Care, INC. | $16.88 | 2023 | T:Slim X2 Insulin Pump With Control-Iq |
| Eusa Pharma (US) LLC | $16.08 | 2022 | |
| Gilead Sciences, INC. | $15.53 | 2019 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $12.91 | 2019 | |
| Valeritas, INC. | $12.19 | 2019 | |
| Medtronic Minimed, INC. | $11.19 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Gary Edelson listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.